The Global Heparin
Market, Product Type (Unfractionated Heparin (UH), Low Molecular Weight
Heparin (LMWH), and Ultra-low Molecular Weight Heparin (ULMW)), by Dosage Form
(Injection and Solutions), and by Region (North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa) was valued at US$ 9.4 billion in 2017,
and is projected to exhibit a CAGR of 5.1% over the forecast period (2018 -
2026).
Heparin is a complex drug, used
as an anticoagulant in blood transfusions, extracorporeal circulation, and
dialysis procedures to prevent and treat various types of blood clots and
atrial fibrillation with embolization. According to CDC, around one million
Americans die each year due to venous thromboembolism (VTE). In June 2017, the
U.S. FDA approved BEVYXXA (betrixaban) for prevention of venous thromboembolism
(VTE) in adult patients, who are at risk for thromboembolic complications due
to moderate or severe restricted mobility and other risk factors for VTE. In
December 2017, Mylan N.V., a global pharmaceutical company, received final
approval from the U.S. FDA for its abbreviated new drug applications (ANDAs)
for Heparin Sodium Injection USP, 1,000 USP/mL, 5,000 USP/mL, 10,000 USP/mL,
and 20,000 USP/mL, all of which are packaged in multi-dose vials. In June 2018,
the company announced the U.S. launch of Bivalirudin for injection, 250 mg
single-dose vial, a generic version of Angiomax from The Medicines Company. The
product is a direct thrombin inhibitor indicated for use as an anticoagulant.
China is a major producer and exporter of heparin.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2602
According to Energy and Commerce
Committee, Chinese supply of heparin to Thailand and Hong Kong increased
rapidly to over 40,000 kilograms and 28,000 kilograms respectively in 2016.
However, in 2017, Energy and Commerce Committee sent a letter to the U.S. Food
and Drug Administration (FDA), sharing information and concerns regarding
China’s market for heparin. Among the concerns reported, include surging
exports of heparin to Hong Kong and Thailand, and the discovery of use of
frozen pig intestines to make heparin by Chinese industry. According to the
committee, about 60% of the crude ingredients used to manufacture heparin in
the U.S. are sourced from China, leaving the U.S. health care system vulnerable
to fluctuations in its supply. With the U.S. reliance on China for heparin, FDA
added heparin to its list of drug shortages in February 2018.
Browse 33 Market Data Tables and
21 Figures spread through 149 Pages and in-depth TOC on "Heparin Market,
by Product Type (Unfractionated Heparin (UH), Low Molecular Weight Heparin
(LMWH), and Ultra-low Molecular Weight Heparin (ULMW)), by Dosage Form
(Injection, and Solutions), and by Region (North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/heparin-market-2602
Key Takeaways of the Heparin
Market:
The global heparin market is
expected to expand at a CAGR of 5.1% during the forecast period (2018–2026),
owing to increasing incidences of coronary heart disease, pulmonary embolism,
and deep vein thrombosis. According to the CDC 2015 report, about 5 to 8% of
the U.S. population had inherited thrombophilias.
Major players operating in the
global heparin market include Anselm Pharmaceuticals, Baxter International
Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories
Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer,
Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United
Biotech (P) Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2602
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
